| Mohammed Alrouji, Debarati DasGupta, Ghulam Md Ashraf, Anwar L Bilgrami, Fahad A Alhumaydhi, Waleed Al Abdulmonem, Moyad Shahwan, Abdulrhman Alsayari, Akhtar Atiya, Anas Shams. Inhibition of microtubule affinity regulating kinase 4 by an acetylcholinesterase inhibitor, Huperzine A: Computational and experimental approaches. International journal of biological macromolecules vol issue 2023 36870649
||thus mark4 plays a key role in alzheimer's disease (ad) pathology.
| Mohd Adnan, Saleha Anwar, Debarati DasGupta, Mitesh Patel, Abdelbaset Mohamed Elasbali, Hassan H Alhassan, Alaa Shafie, Arif Jamal Siddiqui, Fevzi Bardakci, Mejdi Snoussi, Md Imtaiyaz Hassa. Targeting inhibition of microtubule affinity regulating kinase 4 by Harmaline: Strategy to combat Alzheimer's disease. International journal of biological macromolecules vol issue 2022 36257368
||due to its direct role in the hyper-phosphorylation of tau protein, mark4 is considered as an attractive target to fight alzheimer's disease and neuroinflammation.
| Saleha Anwar, Moyad Shahwan, Gulam Mustafa Hasan, Asimul Islam, Md Imtaiyaz Hassa. Microtubule-affinity regulating kinase 4: A potential drug target for cancer therapy. Cellular signalling vol issue 2022 35961526
||aberrant expression of mark4 is linked with several pathologies such as cancer, alzheimer's disease, obesity, etc.
| Farha Naz, Neha Sami, Abu Turab Naqvi, Asimul Islam, Faizan Ahmad, Md Imtaiyaz Hassa. Evaluation of human microtubule affinity-regulating kinase 4 inhibitors: fluorescence binding studies, enzyme, and cell assays. Journal of biomolecular structure & dynamics vol 35 issue 14 2018 27748164
||human microtubule affinity-regulating kinase 4 (mark4) is considered as an encouraging drug target for the design and development of inhibitors to cure several life-threatening diseases such as alzheimer disease, cancer, obesity, and type-ii diabetes.